Physician profile
Rowena Meyer
NPI 1609220037
$12,828.77
in general payments reported to CMS, 2019-2025
35 companies · $5,400 in 2025
The $5,400 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $1,968 · 2023: $1,495 · 2024: $3,146 · 2025: $5,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,540 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,095 · Travel and Lodging: $1,298 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,540.06 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,095.00 |
| Travel and Lodging | $1,298.21 |
| Education | $106.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $6,229.08 | 2022-2025 | Keytruda, Lynparza, Dificid |
| Astrazeneca Pharmaceuticals Lp | $2,680.05 | 2021-2025 | Enhertu, Lynparza |
| Gilead Sciences, INC. | $616.99 | 2021-2025 | Trodelvy |
| Pfizer INC. | $521.26 | 2021-2024 | |
| Daiichi Sankyo INC. | $371.34 | 2021-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $297.18 | 2023-2025 | |
| Lilly USA, LLC | $182.74 | 2021-2024 | Verzenio |
| Stemline Therapeutics INC. | $161.06 | 2025 | Orserdu |
| Glaxosmithkline, LLC. | $160.41 | 2021-2022 | |
| Seagen INC. | $155.39 | 2022-2023 | Adcetris, Tivdak |
| Tempus Ai, INC | $150.93 | 2024 | Xt Cdx |
| Incyte Corporation | $143.08 | 2021-2024 | Pemazyre, Monjuvi, Jakafi |
| Genentech USA, INC. | $142.78 | 2022-2025 | Venclexta, Phesgo, Tecentriq |
| Astellas Pharma US INC | $139.48 | 2022-2024 | Padcev, Xospata |
| Amgen INC. | $132.79 | 2022-2023 | Xgeva, Vectibix, Nplate |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.13 | 2022-2023 | Iclusig |
| Genzyme Corporation | $66.96 | 2021-2023 | |
| Emd Serono, INC. | $54.08 | 2023 | Bavencio |
| Caris Mpi, INC. | $50.07 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $45.23 | 2024 | Ultomiris |
| Abbvie INC. | $44.59 | 2022-2024 | |
| Celgene Corporation | $42.73 | 2021-2024 | Reblozyl |
| Tersera Therapeutics LLC | $38.89 | 2023 | Zoladex |
| Coherus Oncology, INC. | $38.22 | 2021 | |
| Jazz Pharmaceuticals INC. | $37.78 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $33.27 | 2022 | |
| Karyopharm Therapeutics INC. | $32.35 | 2021 | |
| Corcept Therapeutics | $31.28 | 2025 | Korlym |
| Sobi, INC | $28.83 | 2024 | |
| Puma Biotechnology, INC. | $27.10 | 2024 | |
| Pharmaessentia USA Corporation | $25.59 | 2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $23.88 | 2022 | |
| Janssen Biotech, INC. | $19.20 | 2023 | Imbruvica |
| Eisai INC. | $19.18 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.85 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rowena Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.